Evidence map›Paper›PMID 36031390›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

Infants Receiving Very Early Antiretroviral Therapy Have High CD4 Counts in the First Year of Life.

Bryan S Nelson, Camlin Tierney, Deborah Persaud, Jennifer Jao, Mark F Cotton, Yvonne Bryson, Anne Coletti, Theodore D Ruel, Stephen A Spector, Christina Reding and 10 more

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02140255 (Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02140255 phase1 / phase2recruitingnot on this map

Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission: A Phase I/II Proof of Concept Study

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2015 to 2031Enrolled1,120ConditionsHIV InfectionArmsNucleoside Reverse Transcriptase Inhibitors (NRTIs), Nevirapine (NVP), Lopinavir/Ritonavir (LPV/r), Raltegravir (RAL), VRC01
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 12 institutions in 4 countries.

Bryan S NelsonCenter for Biostatistics in AIDS Research in the Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.ORCID 0000-0002-4964-067X
Camlin TierneyCenter for Biostatistics in AIDS Research in the Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Deborah PersaudDivision of Infectious Diseases, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Jennifer JaoDivision of Pediatric Infectious Diseases, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Mark F CottonDepartment of Pediatrics and Child Health, Family Center for Research with Ubuntu, Stellenbosch University, Tygerberg, South Africa.
Yvonne BrysonDepartment of Pediatrics, University of California-Los Angeles David Geffen School of Medicine, Los Angeles, California, USA.
Anne ColettiScience Facilitation Department, FHI 360, Durham, North Carolina, USA.
Theodore D RuelDepartment of Pediatrics, San Francisco School of Medicine, University of California, San Francisco, California, USA.
Stephen A SpectorDepartment of Pediatrics, University of California San Diego School of Medicine, La Jolla, California, USA.
Christina RedingFrontier Science and Technology Research Foundation, Amherst, New York, USA.
Kira BaconFrontier Science and Technology Research Foundation, Amherst, New York, USA.
Diane CostelloIMPAACT Laboratory Center, University of California Los Angeles, Los Angeles, California, USA.
Charlotte PerlowskiScience Facilitation Department, FHI 360, Durham, North Carolina, USA.
Maria Leticia Santos CruzInfectious Diseases Department, Hospital Federal dos Servidores do Estado, Rio de Janeiro, Brazil.
Josphat KosgeiKenya Medical Research Institute/Walter Reed Project, Kericho, Kenya.
Sai MajjiEunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.
Dwight E YinDivision of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.
Patrick Jean-PhilippeDivision of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.
Ellen G ChadwickDivision of Pediatric Infectious Diseases, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
IMPAACT P1115 Team
National Institutes of Health · USCancer Research And Biostatistics · USFamily Health International 360 · USFrontier Science & Technology Research Foundation · USNorthwestern University · USUniversity of California, Los Angeles · USHospital Federal dos Servidores do Estado · BRJohns Hopkins University · USKenya Medical Research Institute · KEStellenbosch University · ZAUniversity of California San Diego · USUniversity of California, San Francisco · US

Funding

LOC-IMPAACT Leadership GroupPharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the USUM1AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI Sharon A Nachman · 2011 to 2026
$278.1M
Statistical and Data Management Center-Pediatric,Adolescent, and Maternal CTGUM1AI068616 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Sean Scott Brummel, Marlene Ann Cooper · 2011 to 2026
$155.6M
University of California, San Diego Clinical Trial UnitUM1AI069536 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI STEPHEN A SPECTOR · 2012 to 2026
$34.0M
NIAID NIH HHS UM1 AI068616NIAID NIH HHS UM1 AI068632NIAID NIH HHS UM1 AI069536NIH HHS UM1AI068632-15
6 · The paper itself

Abstract

We followed 54 infants with in utero HIV after initiating very early antiretroviral treatment. At weeks 24 and 48, ≥80% had CD4 ≥1500 cells/mm3 and CD4% ≥25%. Routine Pneumocystis jirovecii pneumonia prophylaxis in the first year of life may not be necessary for all very early treated infants. CLINICAL TRIALS REGISTRATION: NCT02140255.

Indexed as

Anti-HIV AgentsHIV InfectionsPneumocystis cariniiPneumonia, PneumocystisAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountHumansInfantAnti-HIV AgentsAnti-Retroviral AgentsCD4cotrimoxazoleHIVneonatalPneumocystis jirovecii pneumonia

Identifiers

PMID36031390
PMCPMC10169385
OpenAlexW4293415288

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.